经皮聚桂醇泡沫硬化剂注射治疗浅表动静脉畸形的近期疗效和安全性分析

目的：探讨经皮聚桂醇泡沫硬化剂注射治疗浅表动静脉畸形（AVM）的可行性，并评价其近期疗效和安全性。方法：选取2015年3月至2015年11月于本院血管瘤与脉管畸形专科门诊确诊为外周浅表AVM的患者21例，其中男12例，女9例，年龄1周～56岁，平均37.1岁，7例处于静止期，14例处于扩张期。应用聚桂醇泡沫硬化剂注射治疗，分次进行。所有患者术前、术后均进行了相关辅助检查，分别依据患者临床症状的改善情况和影像学复查病灶的消退情况进行疗效评价。结果：21例患者经皮聚桂醇泡沫硬化剂注射治疗共71次，每例2～5次，平均3.4次。2例治愈，18例好转，1例无效，总有效率为95.2%。1例患者出现术后疼痛，1个月后自行缓解。21例患者注射治疗后均无严重并发症。结论：经皮聚桂醇泡沫硬化剂注射治疗早期浅表AVM有效、并发症少，可以控制病变进一步的发展，甚至可以治愈，有望成为早期浅表AVM的重要治疗方式之一。

Safety and short-term efficacy of direct percutaneous lauromacrogol foam hardening agent injection for the treatment of superficial arteriovenous malformations

Objective: To study the feasibility of direct percutaneous lauromacrogol foam hardening agent injection for the treatment of superficial arteriovenous malformations, and evaluate it’s short-term efficacy and safety. Methods: From March 2015 to November 2015, 21 superficial arteriovenous malformations patients were treated with lauromacrogol foam hardening agent. Among the patients, 12 were male and 9 were female. Their ages were ranged from 1 week to 56 years old, average age was 37.1 years. Seven patients of them were in the quiescence stage, other 14 patients were in the expansion stage. The treatments were divided into several times. All patients were clinically followed-up in preoperation and postoperation by the related auxiliary examination. The effect was respectively evaluated depending on the basis of the improvement of clinical symptoms and imaging review of lesions fading condition. Results: There were 71 times in the treatment of direct percutaneous lauromacrogol foam hardening agent injection for 21 patients in total, 2-5 times per patient, average 3.4 times per patient. Two cases were cured, 18 cases got better, 1 case was invalid, and the total effective rate was 95.2%. One case got postoperative pain, relieved after 1 month by himself, 21 patients had no serious postoperative complications. Conclusion: Direct percutaneous lauromacrogol foamhardening agent injection treatment is expected to be one of the most important treatments for early stage superficial arteriovenous malformations.